Anacetrapib is a novel cholesteryl ester transfer protein (CETP) inhibitor designed for cardiovascular risk reduction and the treatment of hypercholesterolemia and mixed dyslipidemia. The gene discussed is CETP; the disease is familial hypercholesterolemia.